Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

FIVE PRIME THERAPEUTICS INC (FPRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/13/2018 04/16/2018 04/17/2018 04/18/2018 04/19/2018 Date
17.1(c) 17.06(c) 17.35(c) 16.88(c) 16.04(c) Last
246 142 369 023 212 412 191 945 283 774 Volume
+1.18% -0.23% +1.70% -2.71% -4.98% Change
More quotes
Financials (USD)
Sales 2018 78,2 M
EBIT 2018 -135 M
Net income 2018 -146 M
Debt 2018 -
Yield 2018 -
Sales 2019 112 M
EBIT 2019 -107 M
Net income 2019 -107 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 7,58x
Capi. / Sales2019 5,29x
Capitalization 593 M
More Financials
Company
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.The FPA008 is an antibody that inhibits colony stimulating factor-1,... 
More about the company
Surperformance© ratings of Five Prime Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on FIVE PRIME THERAPEUTICS IN
04/19FIVE PRIME THERAPEUTICS : Presents on Novel B7-H4 Therapeutic Antibody at the 20..
AQ
04/17FIVE PRIME THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-..
AQ
04/15FIVE PRIME THERAPEUTICS : Presents on Novel B7-H4 Therapeutic Antibody at the 20..
BU
04/12FIVE PRIME THERAPEUTICS : Personal Genome Diagnostics Announces Collaboration to..
AQ
04/10FIVE PRIME THERAPEUTICS INC : Other Events (form 8-K)
AQ
04/09FIVE PRIME THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-..
AQ
04/03FIVE PRIME THERAPEUTICS : Personal Genome Diagnostics Announces Collaboration to..
PR
04/02FIVE PRIME THERAPEUTICS : Initiates Patient Dosing in Phase 1 Trial of Novel Fir..
AQ
03/30FIVE PRIME THERAPEUTICS : Announces Oral Presentation on FPA150 at the 2018 AACR..
AQ
03/28FIVE PRIME THERAPEUTICS : Initiates Patient Dosing in Phase 1 Trial of Novel Fir..
BU
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/19Five Prime Therapeutics $FPRX Downgraded to “Strong Sell” at ValuEngine  
04/17BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO  
04/16$FPRX: Five Prime Therapeutics gives oral presentation featuring FPA150 at 20..
1
04/15Five Prime Therapeutics : Presents on Novel B7-H4 Therapeutic Antibody at the.. 
04/13Five Prime Therapeutics Inc $FPRX Shares Sold by Bank of New York Mellon Corp.. 
More tweets
Qtime:140
News from SeekingAlpha
03/28COMPUGEN : Near-Term Catalysts Will Force Significant Revaluation 
03/13Five Prime finance chief bids adieu 
03/13Five Prime Therapeutics (FPRX) Presents At 38th Annual Cowen and Company Heal.. 
03/09Key events next week - healthcare (continued #3) 
03/01YOUR DAILY PHARMA SCOOP : Celgene Setback, Valeant Results, Synergy Sells Rights 
Chart FIVE PRIME THERAPEUTICS IN
Duration : Period :
Five Prime Therapeutics In Technical Analysis Chart | FPRX | US33830X1046 | 4-Traders
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 44,7 $
Spread / Average Target 178%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Helen Collins Chief Medical Officer & Senior Vice President
Bryan Irving Senior Vice President-Research
Fred E. Cohen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-20.85%593
GILEAD SCIENCES5.35%98 675
VERTEX PHARMACEUTICALS10.10%41 476
REGENERON PHARMACEUTICALS-14.19%34 613
GENMAB22.84%12 833
BEIGENE LTD (ADR)73.08%9 059